Cell-mediated immunity of patients who have had basal cell carcinomas

Acta Dermato-Venereologica

Volumn 76, Issue 1, 1996, Pages 28-30

  Czarnecki, D ^a,c   Mar, A ^b   Kulinskaya, E ^a  

^a Department of Endocrinology   (Australia)

^b SKIN AND CANCER FOUNDATION   (Australia)

^c NONE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN;

ADULT; ARTICLE; BASAL CELL CARCINOMA; CELLULAR IMMUNITY; CLINICAL TRIAL; COMPLICATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECURRENT DISEASE;

ADULT; ALLERGENS; CARCINOMA, BASAL CELL; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNITY, CELLULAR; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; RISK FACTORS; SKIN NEOPLASMS;

EID: 0029871574     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Robinson JK. Risk of developing another basal cell carcinoma: a five-year prospective study. Cancer 1987; 60: 118-120.
2. Karagas MR, Stubel TA, Greenberg ER, Baron JA, Mott LA, Stern RS. Risk of subsequent basal cell carcinoma and squamous cell carcinoma of the skin among patients with prior skin cancer. JAMA 1992; 267: 3305-3310.
3. Czarnecki D, Mar A, Staples M, Giles G, Meehan C. The development of non-melanocytic skin cancers in people with a history of skin cancer. Dermatology 1994; 189: 364-367.
4. Epstein E. Value of follow-up after treatment of basal cell carcinoma. Arch Dermatol 1973; 108: 798-800.
5. Myskowski PL, Pollack MS, Schorr E, Dupont B, Safai B. Human leukocyte antigen associations in basal cell carcinoma. J Am Acad Dermatol 1985; 122: 997-1000.
6. Cerimele D, Contu L, Costa G, Rossi GC. HLA and multiple skin cancers. Dermatologia 1988; 176: 176-181.
7. Czarnecki D, Lewis A, Nicholson I, Tait B. HLA DR1 is not a sign of poor prognosis for the development of multiple basal cell carcinomas. J Am Acad Dermatol 1992; 26: 717-719.
8. Czarnecki D, Nicholson I, Tait B, Meehan C. No HLA association with the early development of a single basal cell carcinoma. Dermatology 1995: 190: 88.
9. Myskowski PL, Safai B, Good RA. Decreased lymphocyte blastogenic responses in patients with multiple basal cell carcinoma. J Am Acad Dermatol 1981; 4: 711-714.
10. Dellon AL, Potvin C, Chretein PB, Rogentine CN. The immunobiology of skin cancer. Plast Reconstr Surg 1975; 55: 341-352.
11. Angellini G, Vena GA, D'Ovidio R, Lospalluti M, Meneghini CL. T cell subsets and soluble immune response suppressor (SIRS) factor in skin squamous cell carcinoma. Acta Derm Venereol (Stockh) 1983; 63: 109-114.
12. Avgerinou G, Nicolis G, Vareltzidis A, Statigos J. The dermal cellular infiltrate and cell-mediated immunity in skin carcinomas. Dermatologica 1985; 171: 238-242.
13. Moy RL, Abide JM, Bennett RG. T-lymphocyte function and lymphocyte subpopulations with basal cell carcinoma and squamous cell carcinoma. Clin Res 1986; 43: 162A.
14. Anaya F, Perez-Garcia R, Olivas E, Vasconez K, Olivares J. Aparicho JC. Etude de l'hypersensitivité retardée cutanée chez des patients en hemodialyse. Nefrologia 1982; 2 (S) 43.
15. Knicker WT, Anderson CT, McBryde JL, Rourniantzeff M, Lessourd B. Multitest CM1 for standardized measurement of delayed cutaneous hypersensitivity and cell-mediated immunity. Normal values and proposed scoring system for healthy adults in the USA. Ann Allergy 1984; 52: 75-82.
16. Williams DL, Climie A, Muller HK, Lugg DJ. Cell-mediated immunity in healthy adults in Antarctica and the sub-antarctic. J Clin Lab Immunol 1986; 20: 43-49.
17. Watson IPB, Muller HK, Jones IM, Bradley AJ. Cell-mediated immunity in combat veterans with post-traumatic stress disorder. Med J Aust 1993; 159: 513-516.
18. Czarnecki D, Zalcberg J, Kulinskaya E, Kay T. Impaired cell-mediated immunity of apparently normal patients who have had multiple skin cancers. Cancer (in press).
19. Takita H, Brugarolas A. Skin tests in bronchogenic carcinoma: 1. Correlation of the immunological status and the extent of disease. J Surg Oncol 1973; 5: 315-317.
20. Mandel MA, Kiehn CL. The prognostic significance of delayed cutaneous reactivity in head and neck cancer patients. Plast Reconstr Surg 1974: 53: 72-76.
21. Cunningham TJ, Daut D, Wolfgang DE, Mellyn M, Maciolete S, Sponzo RW. Correlation of DNCB-induced delayed cutaneous hypersensitivity reaction and the course of disease in patients with recurrent breast cancer. Cancer 1976; 37: 1696-1700.
22. Morris DL, Hersh EM, Hsi BP, Gutterman J, Marshall MM, Mauligit GM. Recall antigen delayed-type hypersensitivity skin testing in melanoma and acute leukaemia patients and their associates. Cancer Research 1979; 39: 219-226.
23. Blatt SP, Hendrix CW, Butlin CA, Kreeman TM, Ward WW, Hensley RE. Delayed-type hypersensitivity skin testing predicts progression to AIDS in HIV-inlected patients. Ann Int Med 1993; 119: 177-184.
24. Kornbluth RS, McCutchan JA. Skin test responses as predictors of tuberculosis infection and of progression in HIV-infected persons. Ann Int Med 1993; 119: 241-243.
25. Robinson JK, Rademaker AW. Relative importance of prior basal cell carcinomas, continuing sun exposure, and circulating T lymphocytes on the development of basal cell carcinoma. J Invest Dermatol 1992; 99: 227-231.